Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007)

Francesco Grossi; Gianpiero Fasola; Ciro Rossetto; Riccardo Spizzo; Stefano Meduri; Angela Sibau; Enrico Vigevani; Salvatore Tumolo; Gianna Adami; Cosimo Sacco; Leonardo Recchia; Simona Rizzato; Tino Ceschia; Ornella Belvedere

doi:10.1016/j.lungcan.2005.11.013

Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007)

Francesco Grossi, Gianpiero Fasola, Ciro Rossetto, Riccardo Spizzo, Stefano Meduri, Angela Sibau, Enrico Vigevani, Salvatore Tumolo, Gianna Adami, Cosimo Sacco, Leonardo Recchia, Simona Rizzato, Tino Ceschia, Ornella Belvedere

Research output: Contribution to journal › Article › peer-review

Abstract

This study was designed to evaluate the activity and tolerability of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer (NSCLC). Eligibility included recurrent or progressive NSCLC, previous chemotherapy, age ≥18 years, ECOG PS ≤2. Treatment consisted of irinotecan (160 mg/m² i.v.), followed by docetaxel (65 mg/m² i.v.) on day 1 of a 21-day cycle, for a maximum of 6 cycles. Forty patients were enrolled. Median age was 60 years and median ECOG PS was 1. All patients were evaluable for toxicity and 31 (78%) were evaluable for response. A total of 125 cycles was administered (median, 3; range, 1-6). Most common grade 3-4 toxicities were neutropenia (62%), neutropenic fever (22%), and diarrhea (32%). Response rate was 10%; a further 40% of patients achieved stable disease. All responses were observed in patients with ECOG PS ≤1, age

Original language	English
Pages (from-to)	89-92
Number of pages	4
Journal	Lung Cancer
Volume	52
Issue number	1
DOIs	https://doi.org/10.1016/j.lungcan.2005.11.013
Publication status	Published - Apr 2006

Keywords

Docetaxel
Irinotecan
Non-small cell lung cancer
Phase II study
Second line chemotherapy

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/j.lungcan.2005.11.013

Cite this

Grossi, F., Fasola, G., Rossetto, C., Spizzo, R., Meduri, S., Sibau, A., Vigevani, E., Tumolo, S., Adami, G., Sacco, C., Recchia, L., Rizzato, S., Ceschia, T., & Belvedere, O. (2006). Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007). Lung Cancer, 52(1), 89-92. https://doi.org/10.1016/j.lungcan.2005.11.013

Grossi, F, Fasola, G, Rossetto, C, Spizzo, R, Meduri, S, Sibau, A, Vigevani, E, Tumolo, S, Adami, G, Sacco, C, Recchia, L, Rizzato, S, Ceschia, T & Belvedere, O 2006, 'Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007)', Lung Cancer, vol. 52, no. 1, pp. 89-92. https://doi.org/10.1016/j.lungcan.2005.11.013

@article{57f982dd1cdd4068b6d3926bfa6da585,

title = "Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007)",

abstract = "This study was designed to evaluate the activity and tolerability of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer (NSCLC). Eligibility included recurrent or progressive NSCLC, previous chemotherapy, age ≥18 years, ECOG PS ≤2. Treatment consisted of irinotecan (160 mg/m2 i.v.), followed by docetaxel (65 mg/m2 i.v.) on day 1 of a 21-day cycle, for a maximum of 6 cycles. Forty patients were enrolled. Median age was 60 years and median ECOG PS was 1. All patients were evaluable for toxicity and 31 (78%) were evaluable for response. A total of 125 cycles was administered (median, 3; range, 1-6). Most common grade 3-4 toxicities were neutropenia (62%), neutropenic fever (22%), and diarrhea (32%). Response rate was 10%; a further 40% of patients achieved stable disease. All responses were observed in patients with ECOG PS ≤1, age ",

keywords = "Docetaxel, Irinotecan, Non-small cell lung cancer, Phase II study, Second line chemotherapy",

author = "Francesco Grossi and Gianpiero Fasola and Ciro Rossetto and Riccardo Spizzo and Stefano Meduri and Angela Sibau and Enrico Vigevani and Salvatore Tumolo and Gianna Adami and Cosimo Sacco and Leonardo Recchia and Simona Rizzato and Tino Ceschia and Ornella Belvedere",

year = "2006",

month = apr,

doi = "10.1016/j.lungcan.2005.11.013",

language = "English",

volume = "52",

pages = "89--92",

journal = "Lung Cancer",

issn = "0169-5002",

publisher = "Elsevier Ireland Ltd",

number = "1",

}

TY - JOUR

T1 - Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer

T2 - An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007)

AU - Grossi, Francesco

AU - Fasola, Gianpiero

AU - Rossetto, Ciro

AU - Spizzo, Riccardo

AU - Meduri, Stefano

AU - Sibau, Angela

AU - Vigevani, Enrico

AU - Tumolo, Salvatore

AU - Adami, Gianna

AU - Sacco, Cosimo

AU - Recchia, Leonardo

AU - Rizzato, Simona

AU - Ceschia, Tino

AU - Belvedere, Ornella

PY - 2006/4

Y1 - 2006/4

N2 - This study was designed to evaluate the activity and tolerability of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer (NSCLC). Eligibility included recurrent or progressive NSCLC, previous chemotherapy, age ≥18 years, ECOG PS ≤2. Treatment consisted of irinotecan (160 mg/m2 i.v.), followed by docetaxel (65 mg/m2 i.v.) on day 1 of a 21-day cycle, for a maximum of 6 cycles. Forty patients were enrolled. Median age was 60 years and median ECOG PS was 1. All patients were evaluable for toxicity and 31 (78%) were evaluable for response. A total of 125 cycles was administered (median, 3; range, 1-6). Most common grade 3-4 toxicities were neutropenia (62%), neutropenic fever (22%), and diarrhea (32%). Response rate was 10%; a further 40% of patients achieved stable disease. All responses were observed in patients with ECOG PS ≤1, age

AB - This study was designed to evaluate the activity and tolerability of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer (NSCLC). Eligibility included recurrent or progressive NSCLC, previous chemotherapy, age ≥18 years, ECOG PS ≤2. Treatment consisted of irinotecan (160 mg/m2 i.v.), followed by docetaxel (65 mg/m2 i.v.) on day 1 of a 21-day cycle, for a maximum of 6 cycles. Forty patients were enrolled. Median age was 60 years and median ECOG PS was 1. All patients were evaluable for toxicity and 31 (78%) were evaluable for response. A total of 125 cycles was administered (median, 3; range, 1-6). Most common grade 3-4 toxicities were neutropenia (62%), neutropenic fever (22%), and diarrhea (32%). Response rate was 10%; a further 40% of patients achieved stable disease. All responses were observed in patients with ECOG PS ≤1, age

KW - Docetaxel

KW - Irinotecan

KW - Non-small cell lung cancer

KW - Phase II study

KW - Second line chemotherapy

UR - http://www.scopus.com/inward/record.url?scp=33644779559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644779559&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2005.11.013

DO - 10.1016/j.lungcan.2005.11.013

M3 - Article

C2 - 16483688

AN - SCOPUS:33644779559

VL - 52

SP - 89

EP - 92

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 1

ER -

Phase II study of irinotecan and docetaxel in patients with previously treated non-small cell lung cancer: An Alpe-Adria Thoracic Oncology Multidisciplinary group study (ATOM 007)

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this